苯并[D]噻唑-7-胺 | 1123-55-3

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 苯并[D]噻唑-7-胺
• 中文别名: 7-苯并噻唑胺；苯并D噻唑-7-胺
• 英文名称: 7-amino-1,3-benzothiazole
• 英文别名: benzo[d]thiazol-7-amine；7-aminobenzothiazole；benzothiazol-7-ylamine；Benzothiazol-7-ylamin；1,3-benzothiazol-7-amine；azabenzothiazole
• CAS: 1123-55-3
• 化学式: C₇H₆N₂S
• mdl: MFCD10566715
• 分子量: 150.204
• InChiKey: ZWUIKHROIQRWGT-UHFFFAOYSA-N

物化性质

• 熔点：
  122-124℃
• 沸点：
  323℃
• 密度：
  1.383
• 闪点：
  149℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934200090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Benzo[d]thiazol-7-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Benzo[d]thiazol-7-amine
CAS number: 1123-55-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6N2S
Molecular weight: 150.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  苯并[D]噻唑-7-胺 在 盐酸 、 potassium carbonate 作用下， 以 乙醇 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.25h， 生成 9-ethyl-6-oxo-6,9-dihydro-thiazolo[4,5-h]quinoline-7-carboxylic acid
  参考文献：
  名称：

  Synthesis of antimicrobial agents. I. Synthesis and antimicrobial activities of thiazoloquinoline derivatives.

  摘要：

  通过以下两种方法制备了一系列取代的噻唑并[4，5-g]-、[5，4-g]-、[4，5-h]-和[5，4-h]喹啉羧酸，目的是提供新的抗菌药物。其中一种合成方法是通过氨基苯并噻唑与乙氧基亚甲基丙二酸二乙酯缩合、Gould-Jacobs 反应、N-烷基化和水解等连续步骤进行的。另一种是正交氨基巯基喹啉的噻唑环化反应。这项工作中制备的这些化合物在体外进行了抗菌活性评估。9-氯-8-乙基-5, 8-二氢-5-氧代噻唑并-[4, 5-g] 喹啉-6-羧酸（28b）的活性最高。

  DOI：

  10.1248/cpb.27.1
• 作为产物：
  描述：

  7-硝基苯并噻唑 在 盐酸 、 tin(ll) chloride 作用下， 生成 苯并[D]噻唑-7-胺
  参考文献：
  名称：

  Vel'tman,R.P., Journal of general chemistry of the USSR, 1960, vol. 30, p. 1394 - 1397

  摘要：

  DOI：

文献信息

• [EN] PYRIMIDINONE DERIVATIVES AS SHP2 ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIMIDINONE UTILISÉS EN TANT QU'ANTAGONISTES DE SHP2
  申请人：MERCK PATENT GMBH

  公开号：WO2020210384A1

  公开（公告）日：2020-10-15

  The invention relates to pyrimidinone derivatives of the general Formula (II), or a pharmaceutically acceptable salt thereof, the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

  这项发明涉及一般式（II）的嘧啶酮衍生物，或其药学上可接受的盐，以及本发明化合物用于治疗哺乳动物，特别是人类的增殖过度性疾病和紊乱的用途，以及含有这种化合物的药物组合物。
• Regio- and Enantioselective Iridium-Catalyzed Amination of Racemic Branched Alkyl-Substituted Allylic Acetates with Primary and Secondary Aromatic and Heteroaromatic Amines
  作者：Seung Wook Kim、Leyah A. Schwartz、Jason R. Zbieg、Craig E. Stivala、Michael J. Krische

  DOI：10.1021/jacs.8b12152

  日期：2019.1.9

  enantioselective Tsuji-Trost-type aminations of racemic branched alkyl-substituted allylic acetates using primary or secondary (hetero)aromatic amines. Specifically, in the presence of ( S)-Ir-II (5 mol%) in DME solvent at 60-70 °C, α-methyl allyl acetate 1a (100 mol%) reacts with primary (hetero)aromatic amines 2a-2l (200 mol%) or secondary (hetero)aromatic amines 3a-3l (200 mol%) to form the branched products

  由 (S)-tol-BINAP、(S)-Ir-II 改性的空气和水稳定的 π-烯丙基 C,O-苯甲酸酯催化外消旋支链烷基的高度区域和对映选择性的辻-Trost 型胺化-使用伯或仲（杂）芳族胺取代烯丙基乙酸酯。具体而言，在 60-70 °C 下，在 (S)-Ir-II (5 mol%) 的 DME 溶剂中，α-甲基烯丙酯乙酸酯 1a (100 mol%) 与伯（杂）芳族胺 2a-2l 反应(200 mol%) 或仲（杂）芳族胺 3a-3l (200 mol%) 分别形成烯丙基胺化 4a-4l 和 5a-5l 的支化产物，作为单一区域异构体，收率良好至极好，且含量均高的对映选择性。如杂芳胺 3m 转化为加合物 6a-6g 所示，在带有正烷基或仲烷基取代基的各种支链乙酸烯丙酯中保留了出色的区域选择性和对映选择性。对于包含伯和仲芳胺部分的反应物 3n-3p，区域选择性和对映选择性胺化以完全位点选择性发生，以提供加合物
• [EN] ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES<br/>[FR] AGENTS ANTIBACTÉRIENS : N (ALPHA)-AROYL-N-ARYL-PHÉNYLALANINAMIDES
  申请人：UNIV RUTGERS

  公开号：WO2015120320A1

  公开（公告）日：2015-08-13

  The invention provides compounds having activity as bacterial RNA polymerase inhibitors and antibacterial agents, as well as compositions comprising the compounds and methods for their use. Specifically, phenylalanineamide and tyrosinamide compounds are disclosed that have inhibitory activity toward mycobacterium tuberculosis RNA polymerase. Use of these compounds in the treatment o prevention of M. tuberculosis infections in a mammal, is disclosed.

  该发明提供了具有细菌RNA聚合酶抑制剂和抗菌剂活性的化合物，以及包含这些化合物的组合物和它们的使用方法。具体地，揭示了对结核分枝杆菌RNA聚合酶具有抑制活性的苯丙氨酰胺和酪氨酰胺化合物。还揭示了在哺乳动物中使用这些化合物治疗或预防结核分枝杆菌感染的方法。
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK)
  作者：Christopher R. M. Asquith、James M. Bennett、Lianyong Su、Tuomo Laitinen、Jonathan M. Elkins、Julie E. Pickett、Carrow I. Wells、Zengbiao Li、Timothy M. Willson、William J. Zuercher

  DOI：10.3390/molecules24224016

  日期：——

  SGC-GAK-1 (1) is a potent, selective, cell-active chemical probe for cyclin G-associated kinase (GAK). However, 1 was rapidly metabolized in mouse liver microsomes by cytochrome P450-mediated oxidation, displaying rapid clearance in liver microsomes and in mice, which limited its utility in in vivo studies. Chemical modifications of 1 that improved metabolic stability, generally resulted in decreased GAK potency. The best analog in terms of GAK activity in cells was 6-bromo-N-(1H-indazol-6-yl)quinolin-4-amine (35) (IC50 = 1.4 μM), showing improved stability in liver microsomes while still maintaining a narrow spectrum activity across the kinome. As an alternative to scaffold modifications we also explored the use of the broad-spectrum cytochrome P450 inhibitor 1-aminobenzotriazole (ABT) to decrease intrinsic clearance of aminoquinoline GAK inhibitors. Taken together, these approaches point towards the development of an in vivo chemical probe for the dark kinase GAK.

  SGC-GAK-1 (1)是一种针对cyclin G相关激酶（GAK）的有效、选择性、细胞活性化学探针。然而，在小鼠肝微粒体中，1通过细胞色素P450介导的氧化迅速代谢，导致在肝微粒体和小鼠中迅速清除，从而限制了其在体内研究中的实用性。对1的化学修饰改善了代谢稳定性，但通常导致GAK效力降低。在细胞中GAK活性方面效果最好的类似物是6-溴-N-(1H-吲唑-6-基)喹啉-4-胺（35）（IC50 = 1.4 μM），在肝微粒体中显示出改善的稳定性，同时仍保持着在激酶组中的狭谱活性。作为对骨架修饰的替代方案，我们还探索了广谱细胞色素P450抑制剂1-氨基苯并三唑（ABT）的使用，以降低氨基喹啉GAK抑制剂的内在清除率。综合考虑这些方法，指向了开发一种针对暗激酶GAK的体内化学探针的方向。